Purpose: Preclinical studies have suggested that proton pump inhibitors (PPIs) may increase pancreatic cancer risk; however, epidemiological studies are few, with conflicting results. This spurred us to evaluate whether PPI use is associated with an increased risk of pancreatic cancer in a large population-based study.
| Exposure definition
Based on prescriptions dispensed since 1995, ever use of PPIs (including omeprazole, pantoprazole, lansoprazole, rabeprazole, and esomeprazole) was defined as having filled at least one prescription for a PPI prior to the index date. High levels of PPI use were defined as filled prescriptions equivalent to ≥1000 defined daily doses (DDDs), corresponding to approximately 3 years of cumulative use, eg, 20 000 mg of omeprazole or 30 000 mg of lansoprazole. Prescriptions filled within 2 years prior to the index period were disregarded to allow for a minimum of latency time and to minimize reverse causality.
| Potential confounders
Potential confounders included a prior diagnoses of diabetes, alcoholrelated diseases, chronic obstructive pulmonary disorder (COPD), chronic pancreatitis, gallstones, peptic ulcer, helicobacter pylori infection, or hepatitis B and C infection; use of low-dose aspirin, NSAIDs, statins, or HRT (with concomitant drug use defined as ≥2 prescriptions), Charlson comorbidity index (CCI) score (0 low; 1-2 medium; ≥3 high); and highest achieved education (basic, medium, higher, or unknown). For all covariates, information within 2 years prior to the index date was disregarded.
| Statistical analyses
We used conditional logistic regression to calculate ORs and 95% con- We repeated the main analyses for histamine-2-receptor antagonists (never use constituted the reference group), as these agents have similar indications to PPIs and also have the capacity to induce hypergastrinemia. 11 
| Subgroup and sensitivity analyses
We preformed subgroup analyses by age, gender, stage at diagnosis (ie, localized or nonlocalized), calendar year, and no history of diabetes (as patients with diabetes experience an increased risk of pancreatic cancer). 12 Finally, analyses varied the lag time between 0 and 5 years in 6-month intervals.
All analyses were performed using STATA Release 14.1 (StataCorp, College Station, TX, USA). This study was approved by The Danish Data Protection Agency and Statistics Denmark's Scientific Board.
| RESULTS
We identified 10 592 cases of pancreatic ductal adenocarcinoma. 
KEY POINTS
• Preclinical studies suggest that proton pump inhibitors may increase the risk of pancreatic cancer; however, the epidemiologic evidence is sparse and equivocal.
• In this study, use of proton pump inhibitors was not associated with an increased risk of pancreatic cancer.
• A neutral association was also seen between use of histamine-2-receptor antagonists and pancreatic cancer risk.
including NSAIDs and statins. Other characteristics were similar between cases and controls (Supplementary Table 1) .
Compared with nonuse, ever use of PPIs yielded an age-adjusted, sex-adjusted, and calendar period-adjusted (by design) OR for pancre- Table 2 ).
In analyses stratifying by predefined subgroups, associations with PPI use and pancreatic cancer risk remained largely similar ( Table 2) . In summary, we found no evidence of an association between the use of PPIs and pancreatic cancer risk. Results remained consistent across subgroup and in sensitivity analyses. This study should provide some reassurance to both patients and clinicians.
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